Premium
RES‐specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR‐angiography
Author(s) -
Bremer Christoph,
Allkemper Thomas,
Baermig Joerg,
Reimer Peter
Publication year - 1999
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/(sici)1522-2586(199909)10:3<461::aid-jmri30>3.0.co;2-5
Subject(s) - spleen , angiography , medicine , radiology , iron oxide , magnetic resonance imaging , pathology , nuclear medicine , materials science , metallurgy
The purpose of this study was to determine the dependency of liver‐ and spleen‐enhancement on particle size and dose of bolus‐injectable iron oxides designed for blood‐pool MR‐angiography (MRA). The superparamagnetic iron oxide SHU 555 A [particle size 65 nm (group 1)] and three derivatives designed for blood‐pool MRA (groups 2–4) with smaller hydrodynamic diameters (46/33/21 nm) were i.v. injected in New Zealand White rabbits at doses of 10, 20, or 40 μmol Fe/kg bw. MRI was performed before, 2, and 24 hours after contrast application using T1‐weighted SE and T2‐weighted TSE sequences. In addition splenic tissue was harvested post mortem and scanned ex vivo. All iron oxides significantly decreased the SI of liver and spleen in T1‐ and T2‐weighted images at 2 and 24 hours after application of contrast media ( P < 0.01). The signal intensity was inversely related to the dose applied. Decreasing particle size resulted in a lower signal enhancement in liver and spleen. However, ultra‐small superparamagnetic iron oxides suited for blood‐pool MRA (USPIOs, group 4) still revealed a significant signal enhancement in the liver and spleen even 24 hours after contrast application (< − 60%, 40 μmol Fe/kg bw). They might thus be used for comprehensive abdominal studies including contrast enhanced MR‐angiography and RES–specific imaging. J. Magn. Reson. Imaging 1999;10:461–467. © 1999 Wiley‐Liss, Inc.